Key result
Prazosin fails to alter cerebrovascular reactivity but impairs endothelial function via elevated baseline arterial diameter.
Why the study?
To assess the contribution of alpha 1-adrenergic receptors to cerebrovascular CO2 regulation.
RCT
Double-blind
Randomized
Answers are grounded in this paper and cite their sources.
We assessed steady-state hypercapnic cerebrovascular reactivity and cerebral endothelium-dependent function, with and without α 1 -adrenergic blockade (Prazosin), in a placebo-controlled, double-blind, and randomized study, to assess the contribution of α 1 -adrenergic receptors to cerebrovascular CO 2 regulation. After administration of Prazosin, cerebrovascular reactivity to CO 2 was not different compared with placebo despite lower blood flow, whereas cerebral endothelium-dependent function was reduced, likely due to elevated baseline internal carotid arterial diameter. These findings suggest that α 1 -adrenoreceptor activity does not influence cerebral blood flow regulation to CO 2 and cerebral endothelial function.
No takes yet. Share an insight, caveat, or question.
Carr et al. (2022) reported an RCT. Prazosin vs. Placebo was evaluated on Steady-state hypercapnic cerebrovascular reactivity and cerebral endothelium-dependent function. Administration of Prazosin did not alter cerebrovascular reactivity to CO2 compared with placebo, but reduced cerebral endothelium-dependent function due to elevated baseline arterial diameter.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: